Genmab A/S (GNMSF)
OTCMKTS · Delayed Price · Currency is USD
316.00
0.00 (0.00%)
Dec 9, 2025, 4:00 PM EST
Genmab Revenue
Genmab had revenue of $1.02B in the quarter ending September 30, 2025, with 25.25% growth. This brings the company's revenue in the last twelve months to $3.47B, up 18.01% year-over-year. In the year 2024, Genmab had annual revenue of $3.00B with 23.13% growth.
Revenue (ttm)
3.47B
Revenue Growth
+18.01%
P/S Ratio
4.97
Revenue / Employee
1.43M
Employees
2,682
Market Cap
19.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.00B | 564.17M | 23.13% |
| Dec 31, 2023 | 2.44B | 351.45M | 16.83% |
| Dec 31, 2022 | 2.09B | 800.56M | 62.19% |
| Dec 31, 2021 | 1.29B | -372.56M | -22.45% |
| Dec 31, 2020 | 1.66B | 854.43M | 106.10% |
| Dec 31, 2019 | 805.32M | 340.75M | 73.35% |
| Dec 31, 2018 | 464.57M | 83.37M | 21.87% |
| Dec 31, 2017 | 381.20M | -144.81M | -27.53% |
| Dec 31, 2016 | 526.01M | 195.32M | 59.07% |
| Dec 31, 2015 | 330.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Genmab News
- 2 days ago - Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial - GuruFocus
- 2 days ago - Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - Business Wire
- 2 days ago - Genmab : Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL - Nasdaq
- 3 days ago - Genmab (GMAB) Reports Positive Phase 3 Study Results for EPKINLY Therapy - GuruFocus
- 3 days ago - Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire
- 4 days ago - Genmab Reports Promising Clinical Trial Results For Fixed-Duration Epcoritamab In Lymphoma - Nasdaq
- 4 days ago - Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) - Business Wire
- 6 days ago - Genmab A/S at Citi Global Healthcare Conference Transcript - GuruFocus